Omnicom, Validic team up to help pharma marketers tap wearables data

Apple Watch

Everyone in healthcare is trying to figure out wearables, including pharma. Omnicom Health Group is counting on a new partnership with digital health platform Validic to go a long way in helping its drugmaker clients do that.

Of course, the plan extends beyond data from “wearables.” A wide range of personal health monitoring gadgets--including ingestibles, embeddables, sensors, robotics and home health devices--now collect patient data.

“Validic gives us the way to manage any type of device for any disease state in a HIPAA-compliant way and deliver a more comprehensive communications plan,” Jo Ann Saitta, chief digital health office at OmnicomHealthGroup, told FiercePharma.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

She added, “The monitoring of biometric data now feeds the creative and the way in which we have to engage patients and doctors. … It can be very overwhelming. There are tons of wearables, lots of data, and people are asking ‘what do I do with it’ and ‘what if my doctor doesn’t understand it.’ All these things now factor into how we communicate with patients and doctors.”

Along with Validic and other Omnicom partners including IBM Watson, Google and Twitter Health, the agency is coming off the MedTech Expo it sponsored as part of the Cannes Lions Health festival. The topics and discussions presented along with personal monitoring devices included cognitive computing and big data, telemedicine, personalized medicine, virtual and augmented reality and 3-D printing.

“Technology and data are not only changing the delivery of healthcare communications but also changing the delivery of medicine,” Saitta said. “…This is uncharted territory for pharma definitely, but it’s also uncharted territory for a lot of partners in healthcare.”

- see the news release

Related Articles:
Omnicom's healthcare push continues with Rabin Martin buyout
Two agency giants duke it out for GlaxoSmithKline $900M media account
Can pharma + tech wearables be a match made in patient heaven?
Wearable healthcare market to jump to $41B in 2020: Reuters

Suggested Articles

Klick Health has debuted its annual holiday video message for pharma clients and potential employees with a message about being kind.

The Tecentriq-chemo approval is the second one for the Roche PD-L1 drug in front-line NSCLC, following an OK for a regimen that also contains Avastin.

At the current rate, Gilead could switch about 50% to 60% of PrEP users off Truvada by the time Teva launches its 2020 copycat, analysts predict.